Pharmacological antagonism or genetic suppression of LPA1 activity has been shown to reduce brain damage such as brain infarction and functional neurological deficit and to attenuate pain responses in mice with tMCAO challenge [22,23,24]. Here, LPAR1 is linked to brain infarction.